Niamh Chapman

Dr. Niamh Chapman

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Hypertension
Verified
Journal Article
Closed access
NCNiamh Chapman
Niamh Chapman
SCSiew M. Ching
Siew M. Ching
AKAleksandra O. Konradi
Aleksandra O. Konradi
ANAnne Monique Nuyt
Anne Monique Nuyt
TKTaskeen Khan
Taskeen Khan
LBLizzy M. Brewster
Lizzy M. Brewster
Hypertension is the leading risk factor for cardiovascular disease and premature death among women globally. However, there is a fundamental lack of knowledge regarding the sex-specific pathophysiology of the condition. In addition, risk factors for hypertension and cardiovascular disease unique to women or female sex are insufficiently acknowledged in clinical guidelines. This review summarizes the existing evidence on women and female-specific risk factors and clinical management of hypertension, to identify critical knowledge gaps relevant to research, clinical practice, and women’s heart health awareness. Female-specific risk factors relate not only to reproduction, such as the association of gynecological conditions, adverse pregnancy outcomes or menopause with hypertension, but also to the specific roles of women in society and science, such as gender differences in received medical care and the underrepresentation of women in both the science workforce and as participants in research, which contribute to the limited evidence-based, gender- or sex-specific recommendations. A key point is that the development of hypertension starts in young, premenopausal women, often in association with disorders of reproductive organs, and therefore needs to be managed early in life to prevent future cardiovascular disease. Considering the lower blood pressure levels at which cardiovascular disease occurs, thresholds for diagnosis and treatment of hypertension may need to be lower for women.

1 March 2025 in Hypertension
Verified
Journal Article
Closed access
SMShiva Raj Mishra
Shiva Raj Mishra
GSGautam Satheesh
Gautam Satheesh
VVVishnu Vishnu
Vishnu Vishnu
Tu Ngoc NguyenTu Ngoc Nguyen
Tu Ngoc Nguyen
DPDean Picone
Dean Picone
RLRichard I. Lindley
Richard I. Lindley

24 May 2023 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
KWKristyn Whitmore
Kristyn Whitmore
ZZZhen Zhou
Zhen Zhou
NCNiamh Chapman
Niamh Chapman
Quan HuynhQuan Huynh
Quan Huynh
CMCostan G. Magnussen
Costan G. Magnussen
TMThomas H. Marwick
Thomas H. Marwick

9 January 2025 in Global Heart
Verified
Journal Article
Open access
PDF file
ARAndres Rosende
Andres Rosende
CRCesar Romero
Cesar Romero
DDDonald J. DiPette
Donald J. DiPette
JBJeffrey Brettler
Jeffrey Brettler
PSPatrick Van der Stuyft
Patrick Van der Stuyft
POPedro Ordunez
Pedro Ordunez
Background: HEARTS in the Americas is the regional adaptation of the WHO Global HEARTS Initiative, aimed at helping countries enhance hypertension and cardiovascular disease (CVD) risk management in primary care settings. Its core implementation tool, the HEARTS Clinical Pathway, has been adopted by 28 countries. To improve the care of hypertension, diabetes, and chronic kidney disease (CKD), HEARTS 2.0 was developed as a three-phase process to integrate evidence-based interventions into a unified care pathway, ensuring consistency across fragmented guidelines. This paper focuses on Phase 1, highlighting targeted interventions to improve and update the HEARTS Clinical Pathway. Methods: First, the coordinating group defined the project’s scope, objectives, principles, methodological framework, and tools. Second, international experts from different disciplines proposed interventions to enhance the HEARTS Clinical Pathway. Third, the coordinating group harmonized these proposals into unique interventions. Fourth, experts appraised the appropriateness of the proposed interventions on a 1-to-9 scale using the adapted RAND/UCLA Appropriateness Method. Finally, interventions with a median score above 6 were deemed appropriate and selected as candidates to enhance the HEARTS Clinical Pathway. Results: Building on the existing HEARTS Clinical Pathway, 45 unique interventions were selected, including community-based screening, early detection and management of risk factors, lower blood pressure thresholds for diagnosing hypertension in high-CVD-risk patients, reinforcement of single-pill combination therapy, inclusion of sodium-glucose cotransporter-2 inhibitors for patients with diabetes, CKD, or heart failure, expanded roles for non-physician health workers in team-based care, and strengthened clinical documentation, monitoring, and evaluation. Conclusion: HEARTS 2.0 Phase 1 identifies key interventions to integrate and improve hypertension and cardiovascular-kidney-metabolic care within primary care, enabling their seamless incorporation into a unified and effective clinical pathway. This process will inform an update to the HEARTS Clinical Pathway, optimizing resources, reducing care fragmentation, improving care delivery, and advancing health equity, thereby supporting global efforts to combat the leading causes of death and disability.

2 May 2023 in JAMA
Verified
Journal Article
Open access
PDF file
DPDean Picone
Dean Picone
NCNiamh Chapman
Niamh Chapman
MSMartin Schultz
Martin Schultz
Aletta SchutteAletta Schutte
Aletta Schutte
GSGeorge Stergiou
George Stergiou
JSJames Sharman
James Sharman
For clinic and home blood pressure (BP) monitoring, hypertension guidelines recommend using automated upper arm cuff BP-measuring devices that have undergone adequate clinical validation. These validated devices have proven accuracy and greater precision than nonvalidated devices.1,2 Patients may obtain a device by online purchase,3 but recent reports detailed a high prevalence of nonvalidated devices on international e-commerce websites.4,5 However, the availability of nonvalidated and validated devices among the most popular brands sold online is unknown. This study sought to determine the availability, cost, and consumer ratings of devices relative to validation status.

1 January 2025 in Hypertension
Verified
Journal Article
Closed access
ECEleanor Clapham
Eleanor Clapham
DPDean Picone
Dean Picone
SCSamuel Carmichael
Samuel Carmichael
GSGeorge Stergiou
George Stergiou
NCNorm R.C. Campbell
Norm R.C. Campbell
NCNiamh Chapman
Niamh Chapman
BACKGROUND: Patient education is needed to perform home blood pressure measurement (HBPM) according to blood pressure (BP) guidelines. It is not known how BP is measured at home and what education is provided, which was the aim of the study. METHODS: Mixed-methods study among Australian adults who perform HBPM (June to December 2023). Participants completed a 30-item online survey on whether they followed guideline recommendations and the education they received for HBPM. Phone interviews were conducted among a purposive sample to further explore survey topics. RESULTS: Participants (n=350) were middle-aged (58±16 years; 54% women), and most (n=250, 71%) had hypertension. Guideline recommendations for HBPM were not always followed by survey participants. Most participants measured BP seated (n=316, 90%) with the cuff fitted to a bare arm (n=269, 77%). Only 15% measured BP in the morning and evening (n=54) and 26% averaged the BP readings over 7 days (n=90). Interview participants (n=34) described measuring BP at “different times of the day after doing different things.” One-third of participants (n=112, 37%) received education for HBPM, which interview participants described as vague verbal instructions from health care practitioners. Participants who received education did not perform high-quality HBPM. Participants who did not receive education mimicked BP measurement methods of health care practitioners, “I do it the way I’ve seen them do it.” CONCLUSIONS: HBPM is not performed according to guideline recommendations, and adults who received ad hoc education did not perform high-quality HBPM. These findings highlight a need for effective education to support HBPM for clinical decision-making.